Amgen Expands Indian Site with $200 Million Investment
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at the inauguration of the site. The Hyderabad-based facility is expected to have a workforce of around 2,000 by year-end and aims to increase use of AI and data science to support development of new medicines. Amgen's expansion in India comes as the company seeks to harness innovation, talent, and technology between the U.S. and India.
- This significant investment highlights the growing importance of emerging markets like India in the global pharmaceutical industry, where companies can tap into a large and cost-effective market for generic drugs.
- How will Amgen's expanded presence in India impact its ability to navigate the complex regulatory landscape and ensure compliance with evolving intellectual property laws?